Charlotte Nazon

Ms. Charlotte Nazon

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in Cells
Verified
Journal Article
Open access
PDF file
MPMarina Pierrevelcin
Marina Pierrevelcin
QFQuentin Fuchs
Quentin Fuchs
BLBenoit Lhermitte
Benoit Lhermitte
MMMelissa Messé
Melissa Messé
EGERIC GUERIN
ERIC GUERIN
Natacha Entz-WerleNatacha Entz-Werle
Natacha Entz-Werle
Osteosarcoma is the most frequent primary bone tumor diagnosed during adolescence and young adulthood. It is associated with the worst outcomes in the case of poor response to chemotherapy and in metastatic disease. While no molecular biomarkers are clearly and currently associated with those worse situations, the study of pathways involved in the high level of tumor necrosis and in the immune/metabolic intra-tumor environment seems to be a way to understand these resistant and progressive osteosarcomas. In this review, we provide an updated overview of the role of hypoxia in osteosarcoma oncogenesis, progression and during treatment. We describe the role of normoxic/hypoxic environment in normal tissues, bones and osteosarcomas to understand their role and to estimate their druggability. We focus particularly on the role of intra-tumor hypoxia in osteosarcoma cell resistance to treatments and its impact in its endogenous immune component. Together, these previously published observations conduct us to present potential perspectives on the use of therapies targeting hypoxia pathways. These therapies could afford new treatment approaches in this bone cancer. Nevertheless, to study the osteosarcoma cell druggability, we now need specific in vitro models closely mimicking the tumor, its intra-tumor hypoxia and the immune microenvironment to more accurately predict treatment efficacy and be complementary to mouse models.

14 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CNCharlotte Nazon
Charlotte Nazon
MPMarina Pierrevelcin
Marina Pierrevelcin
TWThibault Willaume
Thibault Willaume
BLBenoit Lhermitte
Benoit Lhermitte
NWNoelle Weingertner
Noelle Weingertner
Natacha Entz-WerleNatacha Entz-Werle
Natacha Entz-Werle
Background: Osteosarcomas (OTS) represent the most common primary bone cancer diagnosed in adolescents and young adults. Despite remarkable advances, there are no objective molecular or imaging markers able to predict an OTS outcome at diagnosis. Focusing on biomarkers contributing broadly to treatment resistance, we examine the interplay between the tumor-associated macrophages and intra-tumor hypoxia. Methods: Radiological and immunohistochemical (IHC) data were correlated with the outcome in a retrospective and monocentric cohort of 30 pediatric OTS. We studied hypoxic (pS6, phospho-mTor, HIF-1α and carbonic anhydrase IX (CAIX)) and macrophagic (CD68 and CD163) biomarkers. Results: The imaging analyses were based on MRI manual volumetric measures on axial post-contrast T1 weighted images, where, for each tumor, we determined the necrotic volume and its ratio to the entire tumor volume. When they were above 50 cm3 and 20%, respectively, they correlated with a worse overall survival (p = 0.0072 and p = 0.0136, respectively) and event-free survival (p = 0.0059 and p = 0.0143, respectively). IHC assessments enable a significant statistical link between HIF-1α/CAIX hyper-expressions, CD68+ cells and a worse outcome, whereas activation of mTor pathway was linked to a better survival rate and CD163+ cells. Conclusions: This study evidenced the links between hypoxia and immunity in OTS, as their poor outcome may be related to a larger necrotic volume on diagnostic MRI and, in biopsies, to a specific IHC profile.

6 July 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
CNCharlotte Nazon
Charlotte Nazon
AVAurélie Velay
Aurélie Velay
MRMirjana Radosavljevic
Mirjana Radosavljevic
SFSamira Fafi‐Kremer
Samira Fafi‐Kremer
CPCatherine Paillard
Catherine Paillard

16 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CNCharlotte Nazon
Charlotte Nazon
ASAmelia-Naomi SABO
Amelia-Naomi SABO
GBGuillaume Becker
Guillaume Becker
JLJean-Marc Lessinger
Jean-Marc Lessinger
VKVéronique Kemmel
Véronique Kemmel
CPCatherine Paillard
Catherine Paillard
Background: Hydroxyurea (HU) is a FDA- and EMA-approved drug that earned an important place in the treatment of patients with severe sickle cell anemia (SCA) by showing its efficacy in many studies. This medication is still underused due to fears of physicians and families and must be optimized. Methods: We analyzed our population and identified HU pharmacokinetic (PK) parameters in order to adapt treatment in the future. Working with a pediatric population, we searched for the most indicative sampling time to reduce the number of samples needed. Results: Nine children treated by HU for severe SCA were included for this PK study. HU quantification was made using a validated gas chromatography/mass spectrometry (GC/MS) method. Biological parameters (of effectiveness and compliance) and clinical data were collected. None of the nine children reached the therapeutic target defined by Dong et al. as an area under the curve (AUC) = 115 h.mg/L; four patients were suspected to be non-compliant. Only two patients had an HbF over 20%. The 2 h sample was predictive of the medication exposure (r2 = 0.887). Conclusions: It is urgent to be more efficient in the treatment of SCA, and pharmacokinetics can be an important asset in SCA patients.

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
CPCamille Pacaud
Camille Pacaud
CNCharlotte Nazon
Charlotte Nazon
MPMélanie Pages
Mélanie Pages
JRJérémie Rouger-Gaudichon
Jérémie Rouger-Gaudichon
PBPascale Berthet
Pascale Berthet
CPCatherine Paillard
Catherine Paillard
Bloom syndrome (BS) is a rare genetic disorder associated with an elevated risk of cancer. In a national multicentre study, nine paediatric patients with BS and cancer were analysed. Median age at cancer diagnosis was 12 years. Four of the nine patients were diagnosed with BS prior to cancer detection. Six presented with solid tumours, whilst three had haematological malignancies. Six received polychemotherapy, often with dose reductions. Complications included prolonged aplasia, sepsis and early treatment discontinuation. Two patients received radiotherapy. Four relapsed, and four died, including one toxic death. However, five achieved remission, highlighting the possibility of curative treatment despite significant toxicities.

13 April 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
CCCharlotte Calvo
Charlotte Calvo
CHCléo Hautefeuille
Cléo Hautefeuille
LVLoïc Vasseur
Loïc Vasseur
FCFlorian Chevillon
Florian Chevillon
CNCharlotte Nazon
Charlotte Nazon
JDJean-Hugues Dalle
Jean-Hugues Dalle